Long-Term Assessment of Safety and Physical Function With AMG 108 in RA

Amgen

Status and phase: Completed; Phase 2

Conditions: Rheumatoid Arthritis

Treatments: Drug: AMG 108

Study type: Interventional

Funder types: Industry

Identifiers

NCT00369473

20060119

Details and patient eligibility

About

The purpose of this study is to assess long-term safety of SC AMG 108 in the treatment of RA

Enrollment: 690 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Only subjects eligible for and completing 24 weeks of study 20050168 will be permitted to enroll.

Exclusion criteria

• Subjects not eligible for or not completing 24 weeks of study 20050168 will be excluded.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

690 participants in 2 patient groups

1

Experimental group

Description:

350

Treatment:

Drug: AMG 108

Drug: AMG 108

2

Experimental group

Description:

350

Treatment:

Drug: AMG 108

Drug: AMG 108